Standardising management of consent withdrawal and other clinical trial participation changes: The UKCRC Registered Clinical Trials Unit Network's PeRSEVERE project.

Background/Aims: Existing regulatory and ethical guidance does not address real-life complexities in how clinical trial participants' level of participation may change. If these complexities are inappropriately managed, there may be negative consequences for trial participants and the integrity of t...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Trials Vol. 22; no. 5; pp. 578 - 597
Autores principales: Cragg, William J, Clifton-Hadley, Laura, Dearling, Jeremy, Dutton, Susan J, Gillies, Katie, Hardy, Pollyanna, Hind, Daniel, Holm, Søren, Hood, Kerenza, Kearney, Anna, Lewis, Rebecca, Markham, Sarah, Moreau, Lauren, Pham, Tra My, Roberts, Amanda, Ruddock, Sharon, Sirovica, Mirjana, Sohanpal, Ratna, Tharmanathan, Puvan, Verghis, Rejina
Formato: research tables/charts Journal Article
Publicado: Sage Publications, Ltd. Oct2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188284831&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188284831
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17407745
        AB6
      jtl: Clinical Trials
      issn: 17407745
      maglogo: N
    pubinfo:
      dt: Oct2025
      vid: 22
      iid: 5
      pid: 33180
      pub: Sage Publications, Ltd.
      place: <Blank>
    artinfo:
      ui:
        188284831
        186361707
        188284831
        188284831
        10.1177/17407745251344524
        188284831
      ppf: 578
      ppct: 19
      formats:
      tig:
        atl: Standardising management of consent withdrawal and other clinical trial participation changes: The UKCRC Registered Clinical Trials Unit Network's PeRSEVERE project.
      aug:
        au:
          Cragg, William J
          Clifton-Hadley, Laura
          Dearling, Jeremy
          Dutton, Susan J
          Gillies, Katie
          Hardy, Pollyanna
          Hind, Daniel
          Holm, Søren
          Hood, Kerenza
          Kearney, Anna
          Lewis, Rebecca
          Markham, Sarah
          Moreau, Lauren
          Pham, Tra My
          Roberts, Amanda
          Ruddock, Sharon
          Sirovica, Mirjana
          Sohanpal, Ratna
          Tharmanathan, Puvan
          Verghis, Rejina
        affil: Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
      sug:
        subj:
          Consent (Research) Standards
          Research Dropouts
          Research Subject Retention
          Patient Participation
          Clinical Trials
          Counseling
          Human
          Adult
          Middle Age
          Aged
          Male
          Female
          United Kingdom
          Funding Source
          Cross Sectional Studies
          Qualitative Studies
          Quantitative Studies
          Exploratory Research
          Collaboration
          Research Personnel
          Surveys
          Descriptive Statistics
          Feedback
          Conceptual Framework
          Checklists
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background/Aims: Existing regulatory and ethical guidance does not address real-life complexities in how clinical trial participants' level of participation may change. If these complexities are inappropriately managed, there may be negative consequences for trial participants and the integrity of trials they participate in. These concerns have been highlighted over many years, but there remains no single, comprehensive guidance for managing participation changes in ways that address real-life complexities while maximally promoting participant interests and trial integrity. Motivated by the lack of agreed standards, and observed variability in practice, representatives from academic clinical trials units and linked organisations in the United Kingdom initiated the PeRSEVERE project (PRincipleS for handling end-of-participation EVEnts in clinical trials REsearch) to agree on guiding principles and explore how these principles should be implemented. Methods: We developed the PeRSEVERE principles through discussion and debate within a large, multidisciplinary collaboration, including research professionals and public contributors. We took an inclusive approach to drafting the principles, incorporating new ideas if they were within project scope. Our draft principles were scrutinised through an international consultation survey which focussed on the principles' clarity, feasibility, novelty and acceptability. Survey responses were analysed descriptively (for category questions) and using a combination of deductive and inductive analysis (for open questions). We used predefined rules to guide feedback handling. After finalising the principles, we developed accompanying implementation guidance from several sources. Results: In total, 280 people from 9 countries took part in the consultation survey. Feedback showed strong support for the principles with 96% of respondents agreeing with the principles' key messages. Based on our predefined rules, it was not necessary to amend our draft principles, but comments were nonetheless used to enhance the final project outputs. Our 17 finalised principles comprise 7 fundamental, 'overarching' principles, 6 about trial design and setup, 2 covering data collection and monitoring, and 2 on trial analysis and reporting. Conclusion: We devised a comprehensive set of guiding principles, with detailed practical recommendations, to aid the management of clinical trial participation changes, building on existing ethical and regulatory texts. Our outputs reflect the contributions of a substantial number of individuals, including public contributors and research professionals with various specialisms. This lends weight to our recommendations, which have implications for everyone who designs, funds, conducts, oversees or participates in trials. We suggest our principles could lead to improved standards in clinical trials and better experiences for participants. We encourage others to build on our work to explore the application of these ideas in other settings and to generate empirical evidence to support best practice in this area.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N